France-based group Sanofi today has reported its second quarter financial results to the financial community. The second quarter–like the previous one–saw a steady decline in diabetes/cardiology product sales, which lost 15% in Q2 too, to €1.07bn. By contrast, Genzyme confirms its propelling role for the group, with sales increasing beyond expectations. The Consumer Health division was on the plus side too, with a 4% rise. On the whole, however, the group’s sales have decreased by 2.5%, while net income was stable at €1.56bn. The withdrawal of vaccine Pentaxim has caused the whole vaccine division’s sales to drop (-15.6%); however, the group CEO Olivier Brandicourt still strongly believes in this business. Emerging markets have delivered the strongest results, while the American market has shown severe weakening. Good news have come from the new dermatology drug Dupixent and from the recently-acquired Bioverativ, whose consolidation process is now completed.
(Source: Les Echos, Sanofi)